# OnCo record idea-tnbc-de-escalation-for-exceptional-responders (idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/ideas/idea-tnbc-de-escalation-for-exceptional-responders/>
  a schema:CreativeWork ;
  onco:kind "idea" ;
  schema:identifier "idea-tnbc-de-escalation-for-exceptional-responders" ;
  schema:name "Give exceptional responders less: pembrolizumab omission after complete response, anthracycline-free regimens and chemotherapy omission in lymphocyte-rich stage I disease"@en ;
  schema:description "Two thirds of women treated on the KEYNOTE-522 regimen have no tumour left at surgery and about 92 percent of them are alive without relapse at five years, yet all receive nine more cycles of pembrolizumab. Trials are now testing whether the best responders can stop early, skip the anthracycline, or in lymphocyte-rich stage I tumours skip chemotherapy altogether."@en ;
  schema:url <https://onco.cc/ideas/idea-tnbc-de-escalation-for-exceptional-responders/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://europepmc.org/article/MED/38563834>, <https://clinicaltrials.gov/study/NCT05812807>, <https://clinicaltrials.gov/study/NCT05929768> ;
  onco:tag "tnbc-evidence" ;
  onco:cancers <https://onco.cc/cancers/tnbc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/digital-pathology-ai/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/doxorubicin/> ;
  onco:terms <https://onco.cc/terms/pcr/>, <https://onco.cc/terms/tils/>, <https://onco.cc/terms/de-escalation/>, <https://onco.cc/terms/anthracycline/> ;
  onco:trials <https://onco.cc/trials/keynote-522/>, <https://onco.cc/trials/optimice-pcr/>, <https://onco.cc/trials/scarlet-s2212/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-toxicity-qol/>, <https://onco.cc/bottlenecks/b-dose-optimisation/>, <https://onco.cc/bottlenecks/b-trial-design/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-keynote-522-n-engl-j-med-2020/>, <https://onco.cc/key-papers/paper-keynote-522-n-engl-j-med-2024-update/>, <https://onco.cc/key-papers/paper-cortazar-ctneobc-pcr-pooled-analysis-lancet-2014/>, <https://onco.cc/key-papers/paper-leon-ferre-tils-tnbc-no-chemotherapy-jama-2024/>, <https://onco.cc/key-papers/paper-st-gallen-2023-consensus-ann-oncol-2023/> .